Altimmune ALT
$2.08 +$0.11 (+5.58%)
Market closed · Nov 6, 8:10 pm ET · Last extended-hours $2.07 -0.48%
Open$1.97
Prev close$1.97
Day range$1.95 – $2.10
Volume2.77M
Market cap$404.60M
P/E (TTM)–
Dividend yield–
Earnings
Average move on report day±7.9%last 16 reports
Closed higher11 of 1669% of the time
Best reaction+29.1%
Worst reaction-17.9%
Stock move on the day after each report
| Quarter | Report date | Timing | Implied move | Actual move | Versus implied |
|---|---|---|---|---|---|
| 2026/Q2 | 12 Aug 2026 | Pre Market | ±7.5% | -2.33% | Within range |
| 2026/Q1 | 13 May 2026 | Pre Market | ±9.7% | -1.95% | Within range |
| 2025/Q4 | 5 Mar 2026 | Pre Market | ±12.3% | -17.92% | Bigger than priced |
| 2025/Q3 | 6 Nov 2025 | Pre Market | ±16.7% | +5.07% | Within range |
| 2025/Q2 | 12 Aug 2025 | Pre Market | ±13.1% | +7.10% | Within range |
| 2025/Q1 | 13 May 2025 | Pre Market | ±19.0% | -4.16% | Within range |
| 2024/Q4 | 27 Feb 2025 | None | ±11.4% | +8.08% | Within range |
| 2024/Q3 | 12 Nov 2024 | None | ±15.8% | +29.12% | Bigger than priced |
| 2024/Q2 | 8 Aug 2024 | None | ±16.7% | +15.09% | Within range |
| 2024/Q1 | 9 May 2024 | Pre Market | ±18.9% | +7.82% | Within range |
| 2023/Q4 | 27 Mar 2024 | Pre Market | ±15.4% | +2.77% | Within range |
| 2023/Q3 | 7 Nov 2023 | Pre Market | ±34.6% | +1.12% | Within range |
| 2023/Q2 | 10 Aug 2023 | After Market | ±14.8% | -0.99% | Within range |
| 2023/Q1 | 11 May 2023 | Pre Market | ±17.0% | +7.03% | Within range |
| 2022/Q4 | 28 Feb 2023 | Pre Market | ±24.1% | +6.42% | Within range |
| 2022/Q3 | 10 Nov 2022 | Pre Market | ±14.4% | +9.18% | Within range |
"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.
Fundamentals
Latest reported quarter: Q2, ended Jun 2026
Revenue$0.00-100.0% YoY
Operating profit-$26.23M-14.4% YoY
Net profit-$22.83M-3.1% YoY
Diluted EPS-$0.12+55.6% YoY
Free cash flow-$24.25M-25.3% YoY
Operating cash flow-$24.22M
Revenue, last 8 quarters
Net profit, last 8 quarters
Profitability & balance sheet
Operating margin-323,306.5%
Net margin-296,000.0%
Return on equity-28.9%
Return on assets-25.6%
Return on invested capital-29.2%
Current ratio26.78
Liabilities / assets10.1%
Cash & investments$326.28M
Total debt$35.75M
Net cash (debt)$290.54M
No comments yet — be the first to weigh in on ALT.
Sign in to join the discussion.